Private Wealth Partners LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,475 shares of the company’s stock after buying an additional 250 shares during the period. Private Wealth Partners LLC’s holdings in Johnson & Johnson were worth $3,422,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. Asset Planning Services Inc. LA ADV bought a new stake in Johnson & Johnson during the fourth quarter valued at $4,189,000. Burney Co. raised its stake in Johnson & Johnson by 2.2% in the fourth quarter. Burney Co. now owns 38,001 shares of the company’s stock valued at $4,378,000 after buying an additional 812 shares in the last quarter. Hall Capital Management Co. Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $4,111,000. Comerica Bank raised its stake in Johnson & Johnson by 1.0% in the fourth quarter. Comerica Bank now owns 1,050,457 shares of the company’s stock worth $120,383,000 after buying an additional 10,228 shares during the last quarter. Finally, Vontobel Swiss Wealth Advisors AG raised its stake in Johnson & Johnson by 338.1% in the fourth quarter. Vontobel Swiss Wealth Advisors AG now owns 12,487 shares of the company’s stock worth $1,439,000 after buying an additional 9,637 shares during the last quarter. 66.01% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson (NYSE:JNJ) traded up 0.90% during midday trading on Thursday, reaching $133.35. The company had a trading volume of 4,327,164 shares. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The stock’s 50 day moving average price is $133.33 and its 200-day moving average price is $125.48. The firm has a market capitalization of $359.22 billion, a P/E ratio of 22.41 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.83% and a net margin of 22.52%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.74 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.52%. Johnson & Johnson’s payout ratio is currently 56.76%.

COPYRIGHT VIOLATION NOTICE: “Private Wealth Partners LLC Buys 250 Shares of Johnson & Johnson (NYSE:JNJ)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/03/johnson-johnson-nysejnj-stake-raised-by-private-wealth-partners-llc-updated-updated-updated.html.

A number of research firms have recently issued reports on JNJ. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.90 target price for the company. in a report on Monday, May 8th. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Wells Fargo & Company reiterated a “market perform” rating and set a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. UBS AG reiterated a “buy” rating and set a $136.00 price objective on shares of Johnson & Johnson in a report on Monday, May 15th. Finally, Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $133.72.

In other news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.